Background Proteinuria often changes and is known as a "time-dependent exposure." The effect of time-dependent proteinuria on the risk of future stroke remains unclear. Proteinuria is often detected in patients with diabetes mellitus. The present study was designed to evaluate the association between time-dependent proteinuria and the risk of stroke in a patient cohort with different glucose tolerance status. Methods and Results A total of 82 938 participants, who were free of myocardial infarction or stroke and underwent fasting blood glucose and urinary protein measurements at baseline in the Kailuan study, were enrolled. Proteinuria was determined using urine dipstick tests at baseline and subsequent follow-ups. Time-dependent proteinuria was defined as the status of urine protein updated through the follow-up examinations, separately. Time-dependent Cox regression models were used to analyze the relationship between time-dependent proteinuria and the risk of stroke. During a median follow-up of 8.37 years, 2538 participants developed stroke. After adjusting for confounding factors, the hazard ratio (95% CI) for stroke in time-dependent proteinuria among all participants, and the normoglycemia, prediabetes, and diabetes mellitus populations were 1.68 (1.49-1.89), 1.73 (1.47-2.05), 2.15 (1.70-2.72), and 1.30 (1.03-1.65), respectively. There were interaction effects in patients with normoglycemia and prediabetes compared with those with diabetes mellitus. Findings were similar for ischemic and hemorrhagic strokes and were confirmed in sensitivity analyses. Conclusions Time-dependent proteinuria is an independent risk factor of stroke, especially in the normoglycemia and prediabetes populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670539PMC
http://dx.doi.org/10.1161/JAHA.120.015776DOI Listing

Publication Analysis

Top Keywords

time-dependent proteinuria
28
proteinuria risk
16
risk stroke
12
diabetes mellitus
12
normoglycemia prediabetes
12
proteinuria
10
relationship time-dependent
8
stroke
8
glucose tolerance
8
tolerance status
8

Similar Publications

Aim: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Proteinuria levels show seasonal changes, being lower in summer and higher in winter, but it's unclear how this affects kidney failure risks.
  • A study with over 15,000 patients used statistical models to analyze the relationship between urinary protein levels in different seasons and the incidence of kidney failure.
  • Findings indicated winter protein levels are significantly linked to a higher risk of kidney failure compared to summer, emphasizing the importance of considering seasonal variations in managing chronic kidney disease (CKD).
View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on SAF-189s, an advanced drug in clinical trials aimed at treating non-small cell lung cancer (NSCLC) that is positive for ALK and ROS1 mutations, using population pharmacokinetics (PopPK) to assess its safety and effectiveness.
  • - Researchers analyzed plasma concentration data from 299 patients and 24 healthy individuals, considering various factors like age and prior treatments to understand how these influence the drug's effects and side effects.
  • - Findings indicate that while higher doses (210 mg) resulted in more side effects like hyperglycemia and less tolerability, efficacy appeared to plateau at doses between 80-210 mg, suggesting no significant benefit from increasing the dose further.
View Article and Find Full Text PDF

Dose and Time Effects of Renin-Angiotensin Inhibitors on Patients With Advanced Stages 4 to 5 of Diabetic Kidney Disease.

J Endocr Soc

July 2024

Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622401, Taiwan.

Context: Limited evidence exists regarding the cumulative dosing and duration impact of renin-angiotensin system inhibitors (RASis) on cardiorenal and mortality outcomes in patients with advanced stages (predominantly in stage 5 and a minority in stage 4) of diabetic kidney disease (DKD).

Objective: To retrospectively investigate whether there are dose- and time-dependent relationships between RASis and cardiorenal and mortality outcomes in this population.

Methods: Using Taiwan's national health insurance data in 2000-2017, we analyzed 2196 RASi users and 2196 propensity-matched nonusers among 8738 patients living with diabetes and newly diagnosed with advanced chronic kidney disease (23% stage 4, 77% stage 5).

View Article and Find Full Text PDF

Context: Predicting the progression of chronic kidney disease (CKD) to end-stage kidney disease (ESKD) is crucial for improving patient outcomes.

Objective: To reveal the highly predictive activity of serum bilirubin levels for the progression of CKD to ESKD, and to develop and validate a novel ESKD prediction model incorporating serum bilirubin levels.

Methods: We assessed the relative importance of 20 candidate predictors for ESKD, including serum bilirubin levels, in a CKD cohort (15< eGFR <60 mL/min/1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!